Almirall and Absci partner to develop AI-designed therapeutics for dermatological diseases

Almirall S.A., a global biopharmaceutical company focused on medical dermatology, and Absci Corporation, a generative AI drug creation company, today announced a drug discovery partnership aimed to develop and commercialize AI-designed therapeutics to fight chronic and debilitating dermatological diseases. The partnership combines Absci’s Integrated Drug Creation™ platform with Almirall’s dermatological expertise with the goal of delivering life-changing medicines to patients, marking another step forward in AI drug creation.

source https://www.news-medical.net/news/20231120/Almirall-and-Absci-partner-to-develop-AI-designed-therapeutics-for-dermatological-diseases.aspx

Comments

Post a Comment

Popular posts from this blog

High levels of memory killer cells correlate with better survival in melanoma patients

Our skin contains specialized long-lived killer cells that protect against intruders. Researchers at Karolinska Institutet in Sweden and the University of Copenhagen in Denmark have now identified how these cells are formed, and shown that high levels of memory killer cells in cancer tissue correlate with a better survival rate in people with melanoma. source https://www.news-medical.net/news/20230602/High-levels-of-memory-killer-cells-correlate-with-better-survival-in-melanoma-patients.aspx
Read more

Large language models enhance differential diagnosis, paving the way for AI-assisted medical decision-making

Study explores optimizing large language models (LLMs) for differential diagnosis (DDx), demonstrating their potential in assisting clinicians with accurate disease diagnosis using real-world medical cases. source https://www.news-medical.net/news/20231207/Large-language-models-enhance-differential-diagnosis-paving-the-way-for-AI-assisted-medical-decision-making.aspx
Read more